PTEN/MMAC1 is a recently characterized tumor suppressor. A pseudogene derived from the human PTEN/MMAC1 phosphatase, CPTEN, has been reported. Recent analysis of the pseudogene revealed con¯icting results about the expression of CPTEN. In this study, we show that the PTEN/MMAC1 pseudogene is actively transcribed in all cells and tissues examined. In some cases, pseudogene transcripts were found to represent as much as 70% of the total PTEN/MMAC1 RNA. As CPTEN is transcribed, there is a potential for misinterpretation of PTEN/MMAC1 mutations when RT ± PCR techniques are used, as well as potential for a CPTEN-encoded translation product. Although we were unable to detect a pseudogene protein product in the cell lines examined, a baculovirus produced GST pseudogene fusion protein exhibited phosphatase activity comparable to wild type. The results of this study, taken together, indicate the potential complication of PTEN/MMAC1 molecular analysis caused by the expression of CPTEN.
The tumor suppressor gene, PTEN/MMAC1, located on human chromosome 10q23 was identi®ed based upon somatic mutations in numerous diverse types of human cancers (Cheney et al., 1998; Li and Sun, 1997; Steck et al., 1997; Teng et al., 1997) . Germline mutations in PTEN/MMAC1 result in a variety of genetic disorders, including Cowden's disease and Bannayan-Zonana syndrome which characteristically give rise to multiple benign hamartomas as well as increase susceptibility to breast and thryoid cancers Marsh et al., 1997) . The PTEN/ MMAC1 gene encodes a 403 amino acid protein possessing sequence similarity to several protein phosphatases and has been shown to possess weak dual speci®city protein phosphatase activity in vitro (Myers et al., 1997) .
Recently, a PTEN/MMAC1 related cDNA has been identi®ed which shows the hallmark characteristics of a processed pseudogene (Vanin, 1985; Wilde, 1986) . It has 19 nucleotide dierences causing 12 amino acid changes over the coding region of PTEN/MMAC1 . In addition, this gene lacks the PTEN/MMAC1 initiation methionine and has an intronless genomic sequence (Dahia et al., 1998; Teng et al., 1997; Whang et al., 1998) . Dierent reports have mapped the gene to human chromosome 9p21 (Dahia et al., 1998) as well as 9p13 (Robinson et al., 1993; Rowen et al., 1996) . The PTEN/MMAC1 related cDNA, termed CPTEN, was characterized as a nontranslated processed pseudogene of PTEN/ MMAC1 (Dahia et al., 1998; Whang et al., 1998) . Recently, con¯icting reports regarding transcriptional activity of CPTEN have been published (Dahia et al., 1998; Kim et al., 1998; Whang et al., 1998) . We ®nd by two independent methods, that CPTEN is highly transcribed in at least some tissues and cells, thereby potentially complicating analyses aimed at elucidating the transcriptional expression patterns of the normal PTEN/MMAC1 gene or studies based upon cDNA sequencing to examine potential mutations of the PTEN/MMAC1 gene. The results of this study suggest that the potential presence of CPTEN transcripts in various cell lines and tissues should be considered in any molecular investigation of the PTEN/MMAC1 tumor suppressor.
Transcriptional analysis of CPTEN/MMAC1
To examine the possibility of CPTEN transcription, total and poly(A) + RNA was isolated from various human tissues. Possible DNA contamination was removed by DNase treatment, and reverse transcription followed by PCR (RT ± PCR) was performed to amplify a 516 nucleotide portion of PTEN/MMAC1 and CPTEN transcripts. To distinguish PTEN/ MMAC1 and CPTEN amplicons, the RT ± PCR products were subjected to digestion with the restriction endonuclease, HhaI, which cleaves CPTENspeci®c sequences (Figure 1a and b) . The results revealed that both CPTEN and PTEN/MMAC1 were transcribed in all tissues tested. CPTEN transcripts represented between 12 ± 66% of PTEN/MMAC1 transcripts in total RNA samples and 9 ± 41% in poly(A) + RNA samples (Table 1) . Next, CPTEN transcription was examined in glioblastoma cell lines that have characterized mutations to PTEN/MMAC1 ( Table 2 ). The majority of PTEN/MMAC1-related RNAs detected by this method were CPTEN-speci®c, whereas, in A172 cells, all of the PTEN/MMAC1-related RNAs were of CPTEN origin (Table 1) .
To address the possibility of indeterminate results due to genomic DNA contamination of RNA samples, an alternative method was used to further examine the transcription of CPTEN. Northern blots of poly(A) + RNA isolated from the A172 or U373 glioblastoma cell line were probed with full length CPTEN. We and others have shown PTEN/MMAC1 to have transcript sizes of approximately 8, 6, 4, 2.4 and 1.8 kb ( Figure  2a ) (Furnari et al., 1997) . Our Northern blot resulted in a transcript of 1.8 kb, indicating that, at least in the A172 human cell line, the pseudogene is responsible for a single transcript (Figure 2b ). This, along with the RT ± PCR data, strongly support the active transcription of CPTEN. In other cell lines or tissues, the pseudogene could contribute to one or more of the transcripts reported for PTEN/MMAC1. Analysis of the 5' UTR of CPTEN reveals several potential splice sites (CAGs preceded by polypyrimidines) (Solovyev and Salamov, 1997) at positions 146, 414, 833 and 837 ( Figure 3a ). Further analysis indicated the presence of potential RNA polymerase II promoters with predicted start sites at positions 358, 371, 373 and 489 (Solovyev and Salamov, 1997) (Figure 3a) . The 3' UTR of CPTEN contains several consensus polyadenylation sites in regions homologous to those found for PTEN/ MMAC1 (Figure 3c ). These sequence characteristics oer many possible transcript sizes of CPTEN.
Analysis of CPTEN/MMAC1 expression
The detection of a poly(A) + transcript (Figure 2a) , the presence of a ribosomal recognition site (CUG), and/or potential initiation methionine at position 35 ( Figure  3a and b) supported the possibility that CPTEN might be translated. We ®rst tested whether CPTEN would be recognized by PTEN/MMAC1 antibodies. Human transformed primary embryonic kidney cells, 293T, were transfected with a CPTEN construct which expressed amino acids 35 ± 403. Lysates were immunoprecipitated and immunoblotted with PTEN/MMAC1 antibody which recognized a speci®c protein of *53 kD (Figure 4a ), indicating that if expressed, the Figure 1 Diagnostic restriction enzyme digest of CPTEN and PTEN/MMAC1. Commercially available RNA, or total RNA isolated from cells by RNeasy (Qiagen), was DNase treated (Pharmacia), phenol chloroform extracted and ethanol precipitated. RNA was reverse transcribed (RT) with Superscript II RT (Gibco, BRL) followed by PCR ampli®cation with CPTEN speci®c primers; RT: ts seq8 (5'-GTATCGGTTGGCTTTGTC-3'), PCR: ts3mutatg (5'-CGGGATCCACAGCCATCATCAAAGAGATCG-3') and Race 6 (5'-GCCTCTGACTGGGAATAGTTAC-3'). PCR products were TA cloned (Invitrogen) and individual positive colonies were subjected to colony PCR with vector primers (T7: TAATACGACTCACTATAGGG and M13 Reverse: CAGGAAACAGCTATGAC). The resultant amplicons were digested with a pseudogene speci®c restriction site, HhaI. (Figure 4b ). These results together indicate that while CPTEN is actively transcribed, a protein product is undetectable in these cell lines. However, we cannot rule out its potential expression in other cell lines, tissues or stages of development.
Analysis of CPTEN/MMAC1 phosphatase activity
Because the region encoding the catalytic core (IHCKAGKGRTG) required for phosphatase activity (Myers et al., 1997) was intact in CPTEN (Figure 3b) , it was possible that if the protein were expressed, it could retain phosphatase activity. To assay for in vitro phosphatase activity, recombinant CPTEN, PTEN/ MMAC1 and C124S PTEN/MMAC1 (Morimoto et al., 1998) were produced in Sf9 insect cells and the puri®ed proteins were assayed for phosphatase activity against poly (E:Y). While the C124S mutant control showed no activity, CPTEN displayed catalytic activity similar to PTEN/MMAC1 (Figure 5 ), indicating that if expressed, CPTEN would retain in vitro phosphatase activity.
CPTEN has been reported as a processed pseudogene of PTEN/MMAC1. Here, we have used two independent methods to show that CPTEN is actively transcribed. Sequence analysis indicates the presence of potential transcription start sites, as well as possible translational initiation sites. Although we were unable to detect a protein product in the cell lines tested, an in vitro produced pseudogene fusion protein retained catalytic phosphatase activity.
Recently, other groups have detected the sequence changes between PTEN/MMAC1 and CPTEN and ascribed them to novel mutations in PTEN/MMAC1 involved in breast cancer (Rhei et al., 1997) . This study is based on data from RT ± PCR, which stresses the point that this method is not accurate in ascribing mutations of PTEN/MMAC1. Other groups have proposed CPTEN to be a PTEN/MMAC1 homologue, based on sequence similarities and the lack of a detectable intronless product from small cell lung carcinoma genomic DNA (Kim et al., 1998) . In contrast to this study, based on hallmark sequence characteristics of processed pseudogenes which CPTEN displays, along with the detection of an intronless PTEN/MMAC1 product from genomic DNA, we and others (Dahia et al., 1998; Teng et al., 1997; Whang et al., 1998) believe this gene to be a pseudogene of PTEN/MMAC1 rather than a homologue. Figure 4 Analysis of potential translation of CPTEN. Cells were lysed in 1% NP-40 and lysates were immunoprecipitated with rabbit anti-PTEN/MMAC1 antibody (Morimoto et al., 1998) . Proteins were separated by SDS ± PAGE, transferred to nitrocellulose, and immunoblotted using anti-PTEN/MMAC1 primary antibody at a dilution of 1 : 500. Figure 1b) , WT PTEN/MMAC1 and C124S mutant of PTEN/MMAC1 (Morimoto et al., 1998) were cloned into pVLG for baculovirus expression in SF9 insect cells. The fusion proteins were puri®ed using Glutathione-Sepharose beads (Pharmacia). Poly EY (4 : 1) coated 96 well plates (NEN) were phosphorylated with puri®ed GST-lck enzyme (Spana et al., 1993) . Puri®ed PTEN/MMAC1 or control buer was added to the wells, and the reactions incubated at room temperature for 30 min. The amount of phosphorylated poly E:Y remaining was determined using a Top-Count 96-well plate reader (Packard). Bars represent the % an in vitro substrate, poly (E:Y), was dephosphorylated by each puri®ed recombinant protein. Buer was used as a negative control (Control). These results represent data from two experiments with eight duplicate samples for each enzyme used Our results dier from others (Dahia et al., 1998; Whang et al., 1998) as we ®nd CPTEN to be actively transcribed. Whang et al. detected CPTEN transcription by RT ± PCR, but concluded that genomic DNA contamination in RNA samples could be the source of their result. Our data from RT ± PCR in combination with Northern blots, which would not be aected by genomic DNA contamination, strongly support the transcription of CPTEN. It is unclear why Dahia et al. were unable to detect a CPTEN transcript from A172 cells by RT ± PCR as we were able to detect CPTEN transcripts from this cell line by both RT ± PCR and Northern blot. It is clear that the existence of CPTEN may complicate analysis of PTEN/MMAC1 mutational status, as stated by Whang et al. (1998) and Dahia et al. (1998) . However, since we ®nd CPTEN to be actively transcribed, our study raises a particular concern if the data generated contains a transcriptional element. We propose to accurately screen for PTEN/MMAC1 mutations, one must amplify individual exons from genomic DNA, using intronic primers. PTEN/MMAC1 has been shown to be a tumor suppressor (Cheney et al., 1998) . Should a pseudogene protein product be detected in the future, examination of its functional role as well as a comparison with PTEN/MMAC1's tumor suppressor capability would be very interesting, as we have shown that CPTEN retains catalytic activity. Interestingly, Merlo et al. (1994a,b) have reported examples of lung cancer with several regions of chromosome 9 deleted. These observations raise the possibility that chromosome 9 may contain tumor suppressors in addition to p16 (Cairns et al., 1995; Cheng et al., 1994; Kamb et al., 1994; Merlo et al., 1995) . It remains to be determined if CPTEN might play some role in these disease processes.
Abbreviations CPTEN, PTEN/MMAC1 pseudogene; PCR, polymerase chain reaction; poly(A) + , polyadenylated; UTR, untranslated region; RT, reverse transcription; SSC, (3 M Sodium Chloride, 0.3 M Sodium Citrate); SDS, Sodium dodecyl sulfate; poly (E:Y), poly glutamate:tyrosine).
